The type IV ATX inhibitor GLPG1690 (ziritaxestat) was the first ATX antagonist used in humans and showed promising results in a phase 2a randomized placebo-controlled trial to treat idiopathic pulmonary fibrosis [60]. The gene discussed is ENPP2; the disease is pulmonary fibrosis.